Company: WHWK
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001628280-25-020311
Chunk: 44

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 44
---
 issuance under the 2021 Plan and the amended default annual automatic share reserve is not reflected in the table below.

| Plan Category                                                    |     | (a) Number of securities 
 to be issued upon        
 exercise of              
 outstanding options,     
 warrants and rights      |           |     |    | (b) Weighted average 
 exercise price of    
 outstanding options, 
 warrants and rights  |       |     | (c) Number of securities 
 remaining available      
 for future issuance      
 under equity             
 compensation plans       
 (excluding securities    
 reflected in column (a)) |           |     |    |
|:-----------------------------------------------------------------|:----|:-------------------------|----------:|:----|---:|:---------------------|------:|:----|:-------------------------|----------:|:----|---:|
| Equity compensation plans approved by security holders (1)(2)(3) |     |                          | 4,716,506 |     |    | $                    | 11.53 |     |                          | 1,823,798 |     | -4 |
| Equity compensation plans not approved by security holders       |     |                          |   519,167 |     | -5 | $                    |  4.47 |     |                          |   110,000 |     |    |
| Total                                                            |     |                          | 5,235,673 |     |    |                      |       |     |                          | 1,933,798 |     | -4 |

(1) Includes the following plans: Amended and Restated 2014 Equity Incentive Plan, 2017 Stock Option and Incentive Plan, 2021 Plan, and 2021 ESPP.

(2) Our Board adopted, and our stockholders approved, our 2021 Plan. The 2021 Plan provides that the number of shares available for issuance under the 2021 Plan will be increased on the first day of each fiscal year beginning on January 1, 2022, in an amount equal to the least of (i) 2,070,784 shares, (ii) four percent (4%) of the outstanding shares of common stock on the last day of the immediately preceding fiscal year (five percent (5%) following the February 28, 2025 stockholder approval of the amendment to the 2021 Plan) or (iii) such number of shares determined by our Board no later than the last day of the immediately preceding fiscal year. On January